X

Drug Profile

OPHD 001

Alternative Names: Clostridium difficile antibodies - Promega

Latest Information Update: 22 Nov 2006

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Promega Corporation
Class Antibacterials; Antibodies
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Clostridium difficile infections

Most Recent Events

08 Jun 2000 Ophidian has suspended research and product development operations
08 Jun 2000 Suspended-I for Clostridium difficile infections in USA (PO)
11 Jun 1999 OPHD 001 has been named as Ophidian Pharmaceuticals' lead drug candidate for the treatment of Clostridium difficile

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com